Supplemental Table 2.

Duration of Therapy by Age^a (n = 84)

Variable	Therapy Duration, mo
	Age < 75 y (n = 47)	Age ≥ 75 y (n = 37)
PI therapy, including bortezomib-based inductionb
Mean ± SD	10.8 ± 5.6	9.3 ± 5.6
Medianc	9.2	6.8
Range	3.0-22.6	2.6-26.4
IRdd
Mean ± SD	8.0 ± 5.7	6.4 ± 5.6
Medianc	6.3	3.9
Range	0.03-19.9	0.03-23.0
Ixazomibe
Mean ± SD	7.8 ± 5.7	6.0 ± 5.7
Medianc	6.1	3.7
Range	0.03-19.8	0.03-22.8

Abbreviations: IRd = ixazomib, lenalidomide, dexamethasone; PI = proteasome inhibitor; SD = standard deviation.

^aPatients had to continue receiving ixazomib to remain in the study; a dose interruption of ixazomib lasting > 3 weeks or an interruption at the principal investigator’s discretion was considered discontinuation from ixazomib treatment and the patient was discontinued from the study, although they could be followed up for progression-free and overall survival. In addition, at the discretion of the treating physician, patients could discontinue treatment from lenalidomide and/or dexamethasone but continue ixazomib treatment and remain in the study.

^bTime from the date of the first administration of the bortezomib-based induction regimen to the date of the last administration of ixazomib, lenalidomide, or dexamethasone.

^cSimple median (ie, not determined using Kaplan-Meier method).

^dTime from the date of the first administration of IRd to the date of the last administration of ixazomib, lenalidomide, or dexamethasone.

^eTime from the date of the first administration of ixazomib to the date of the last administration of ixazomib.